Nonvitamin K antagonist oral anticoagulants (NOACs) are now available for the prevention of stroke in patients with atrial fibrillation (AF) as an alternative to vitamin K antagonists (VKA) and aspirin. The comparative effectiveness and safety in daily practice of these different drug classes is still unclear. The objective of this study was to evaluate the risk of major bleeding and stroke in AF patients using NOACs, VKAs or aspirin.
Introduction
Atrial fibrillation (AF) has a prevalence of 1-2% and is associated with a doubled rate of death and a 5-fold increased rate of stroke [3, 4] . Antithrombotic therapy such as vitamin K antagonists (VKAs), nonvitamin K antagonist oral anticoagulants (NOACs) and low dose aspirin are used treatment options for AF and can reduce stroke rates by up to 20%-60% [5] [6] [7] . The CHA 2 DS 2 -VASC risk score guides the choice of antithrombotic treatment using known risk factors for stroke: congestive heart failure, hypertension, age, diabetes, prior stroke or thromboembolism, vascular disease and female sex.
Studies have shown that NOACs may significantly reduce the risk of stroke and intracranial bleeding, when compared with warfarin [8] [9] [10] [11] . In line with these findings the European guidelines now recommend using NOACs over VKAs for most patients with AF (2) . The use of aspirin was used only in the treatment of patients at low risk for stroke, however, more recently it is advised that aspirin should be confined to those that refuse NOAC or VKA therapy.
While NOACs are effective in reducing stroke risk, the evidence remains inconclusive with respect to its risks of major and gastrointestinal bleeding [8, 9, [11] [12] [13] [14] [15] [16] . This complicates the choice in antithrombotic therapy in daily practice as the harm-benefit ratio is uncertain in patients with higher baseline risks for bleeding. Furthermore, the risk of antithrombotic therapy in real world patients may differ from those in the randomized controlled trials (RCTs). Patients in RCTs using warfarin spent more time in the therapeutic range compared with patients monitored by community physicians [17] . Secondly, patients who are seen in everyday clinical practice have a different risk profile, as the patients in the trials were obligated to meet specific inclusion and exclusion criteria [18] .
To investigate the safety and efficacy of NOACs compared with VKA in real-world patients, several observational studies have been conducted, but these were limited to the evaluation of dabigatran, and they were unable to statistically adjust for life style factors such as body mass index and smoking status [12] [13] [14] [15] [16] .
The aim of this study was to evaluate the risk of major bleeding and stroke in AF patients using VKAs, NOACs and low dose aspirin in a UK general practice population.
Methods

Data source
We conducted a retrospective cohort study within the Clinical Practice Research Datalink (CPRD). This database contains computerized medical records of around 674 primary care practises in the UK, covering 11.3 million patients, representing 6.9% of the total UK population [19] . Data recorded in the CPRD include demographic information, laboratory tests, specialist referrals, hospital admissions, prescription details, and lifestyle variables such as body mass index (BMI), smoking, and alcohol consumption. Previous studies have shown a high validity of registration and high degrees of accuracy and completeness of these data have been shown for various diagnoses (including 85.3% for diagnoses related to the circulatory system and 87.4% for diagnoses related to the digestive system) and for smoking status [19] [20] [21] [22] [23] .
Study population
The study population consisted of all patients aged ≥18 years with a first ever recorded diagnosis of AF during a patient's period of valid data collection. Only patients with follow-up time between 18 th March 2008 (the date of market introduction of the NOACs) and 1 October 2014 were included. Within this cohort of AF patients, we identified new users of antithrombotic drugs: VKAs, NOACs and low dose (≤325 mg) aspirin. New users were defined as patients who had never been exposed previously to any one of the drugs of interest.
Exposure
Patients were followed from the start of antithrombotic treatment until the end of follow-up, death, or an outcome of interest, whichever date came first. The period of follow-up was divided into 30-day periods, starting with the index date. At the start date of each period, exposure to antithrombotic agents in the 30 days before was defined as current users and past users were defined as those who had discontinued their antithrombotic agents >30 days before the start of the interval. An example of exposure definition for a hypothetical patient is given in Figure 1 . During follow-up, patients were able to move between current and past exposure groups.
Patients were defined as current users of VKA only (warfarin, acenocoumarol and phenindione), NOAC only (dabigatran, rivaroxaban and apixaban), aspirin only, or mixed use of more than one of the three main study drugs. These groups were identified regardless of past use as it is expected that medications taken >30 days from an exposure period would no longer impact a patient's likelihood for the outcome. Patients could only contribute to one current user group during an interval. Among patients who were not considered current users, past use was defined as past VKA, NOAC, or aspirin use, and patients could contribute to more than one past user group in an interval.
Outcomes
The primary outcome of interest was major bleeding. Secondary outcomes were gastrointestinal bleeding, intracranial bleeding, stroke, ischaemic stroke and haemorrhagic stroke. The UK Read code system was used to define outcomes. Major bleeding was defined as a bleeding at a critical site or organ and the selected Read-codes were reviewed by a clinician for relevancy. The codes used for defining the primary outcome can be found in Appendix 1.
Potential confounders
Potential confounders considered in this study were based on literature review. The presence of a covariate was assessed by reviewing the computerized medical records for any record of a covariate. For each outcome, sex, BMI, smoking status and alcohol status were considered at baseline and age at the start of each interval. The following covariates were evaluated prior to the start of each interval for bleeding outcomes: oesophagitis, gastritis, cerebrovascular disease and malignancies. The use of the following prescription drugs in the 6 months before an interval were considered: statins, calcium channel blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin II (ATII) blockers, diuretics, β-blockers, antiplatelet drugs (excluding aspirin), anticoagulant drugs (excluding VKAs and NOACs), antiarrhythmic drugs, nitrates, antidiabetic drugs, nonsteroidal antiinflammatory drugs (NSAIDs), systemic glucocorticoids, selective serotonin reuptake inhibitors (SSRIs). Proton-pump inhibitors and histamine 2 receptor antagonists were assessed in the 3 months before an interval. For stroke, covariates included history of congestive heart failure, hypertension, cerebrovascular disease, ischaemic heart disease, peripheral
Figure 1
Diagram of exposure definition demonstrating a hypothetical case example of a patient classified as oral anticoagulants user at time of a stroke or bleeding event E. M. Gieling et al. 
Statistical analysis
The outcomes of interest were incident first-ever events; patients with a history of the outcome were excluded. 
Patient involvement
For this study, we did not actively involve patients.
Results
We identified 31 497 patients with an AF diagnosis and a firstever prescription of antithrombotic therapy. Figure 2 shows the study flowchart. Baseline characteristics are presented in Table 1 . At the index date, 16 094 (51.1%) patients were prescribed aspirin, 13 643 (43.3%) VKAs, 1306 (4.1%) NOACs, and 453 (1.4%) a mix of these agents. In the NOACs group 28.5% of patients were using dabigatran and 71.5% rivaroxaban. None were using apixaban. The mean duration of follow-up was shorter for users of NOACs (1.0 years) than for users of VKAs (2.7 years) or aspirin (2.8 years). Age, BMI, smoking status and alcohol use did not differ much between exposure groups at baseline. Users of NOACs (18.9%) had more often a history of cerebrovascular disease as compared with users of VKAs (13.4%) or low dose aspirin (6.1%). Appendix 2 shows baseline characteristics of the two cohorts excluding history of the respective outcomes, stroke or major bleed.
The incidence rate for major bleeding per 1000 personyears was 10.6 for current NOAC use, 5.8 for current VKA use, 7.5 for current aspirin use and 8.2 for current mixed use ( Table 2) . A 2-fold increased risk of major bleeding was found with current use of NOACs [adjusted hazard ratio (HR) 2.08; 95% confidence interval (CI) 1.28-3.40], which dropped after discontinuation (HR 1.13; 95% CI 0.42-3.05). Current use of aspirin did not have an increased risk of major bleeding (HR 1.05; 95% CI 0.84-1.32), as compared with current use of VKAs. The doubled risk of major bleeding with current users of NOACS was largely explained by an increased risk for gastrointestinal bleeding (HR 2.63; 95% CI 1.50-4.60) for current NOAC users as compared with current VKA users. No difference was found for the occurrence of intracranial Figure 2 Flow diagram of cohort assembly bleeding in current users of NOACs as compared with current use of VKAs (HR 1.39; 95% CI 0.55-3.52). Table 3 shows that there was no difference in the risks of ischaemic and haemorrhagic stroke between current use of NOAC and VKA (HR 1.22, 95% CI 0.67-2.19 and HR 1.56, 95% CI 0.61-3.99, respectively). The risk of ischaemic stroke was doubled with current use of low dose aspirin compared with current use of VKAs (HR 2.18; 95% CI 1.72-2.39). A higher risk was also found for past use of low dose aspirin compared with current use of VKA (HR 1.65; 95% CI 1.38-1.97).
Results stratified by sex (Table 4) showed that the risk of major bleed in NOAC users was elevated in women (HR 3.14, 95% CI 1.76-5.60) but not in men (HR 0.94, 95% CI 0.34-2.59). Table 5 shows the results stratified by CHA 2 DS 2 -VASc risk score. Current NOAC users with a high stroke risk (CHA 2 DS 2 -VASc >3) had a higher risk of major bleeding compared with current VKA users with a high stroke risk (HR 2.62, 95% CI 1.41-4.87). Across all risk categories, current low dose aspirin use showed an increased risk for ischaemic stroke compared with current VKA use.
Discussion
This study showed a tw2o-fold increase in the risk of major bleeding with current NOAC use compared with current VKA use. This was largely explained by the increase in gastrointestinal bleeding risk; there was no difference in intracranial haemorrhage risk. The increased risk of gastrointestinal bleeding diminished after NOAC discontinuation, as expected. NOACs were equally effective as VKA in the prevention of ischaemic stroke, whereas aspirin was less effective. Our results further suggest that the increased risk for bleeding for NOAC users was restricted to women.
Our main finding of an increased risk of major bleed is not in line with a large meta-analysis from four phase III randomized trials of four different NOACs (dabigatran, rivaroxaban, apixaban, edoxaban) [10] . This study showed that the risk of major bleeding was lower compared with warfarin. A 52% decreased risk for intracranial haemorrhage was found with the usage of NOACs compared with warfarin, although the risk of gastrointestinal bleeding was found to be increased with 25%, which is in line with the results from the current study. Patients who were prone to bleeding were excluded from the clinical trials. Although we have excluded patients with a history of a major bleeding event, we did not exclude patients with other comorbidities (e.g. renal failure, malignancies, gastritis) or concomitant medication (NSAIDs, SSRIs) that increases the risk of bleeding, which might have selected patients with a different baseline risk. In contrast to the trials, we excluded patients with prior events of interest and therefore our results are not directly comparable with the results from the trials. 
Risk of bleeding and stroke of anti-thrombotic treatment
Several observational studies have been carried out that assessed the bleeding risk of NOACs compared with warfarin. A study using US Medicare data compared dabigatran with warfarin and found results that were partially in line with our findings. In this study, an increase in gastrointestinal bleeding was found as well (HR 1.28, 95% CI 1.14-1.44), but a decrease in intracranial bleeding (HR 0.34, 95% CI 0.26-0.46) was shown [16] . No difference for gastrointestinal bleeding was found in a study using Optum Labs Data Warehouse data (a different claims database) in the USA [14] . Similar to the current study, the two observational studies mentioned above used a new user design. By excluding all previous users, the effects of switching and long-term use are reduced. However, in this study we not only identified new users of NOACs and VKAs, but additionally we excluded patients who had used aspirin before. Also the in-or exclusion of prior events of the outcome might be a reason for differences in bleeding risks. The results on major bleeding may strongly depend on the definition of this outcome, and this may explain some of the discrepancies in the current body of literature on this outcome. The most common definition of major bleeding is that of the International Society of Thrombosis and Haemostasis including bleeding at critical sites, need for transfusion of more than two units of blood and a fall in haemoglobin level of >20 g l À1 [24] . This definition, or a derivate of this definition, is used in the different trials comparing VKAs and NOACs [25] [26] [27] . In the current study, we used the Read coding system as opposed to the other observational studies that use ICD-9-CM (international classification of diseases, 9 th revision, clinical modification) codes [14, 16] , which might explain variation in results. This study underlines that NOACs are equally effective in reducing ischaemic stroke as VKAs as is found in meta- analyses of RCTs [10, 28] . Similar results were found in a study undertaken in new users of warfarin from the Danish registry [13] . The >2-fold increased risk of ischaemic stroke with aspirin use is in line with a Cochrane review that shows less frequent ischaemic stroke for oral anticoagulants (all VKAs) when compared with antiplatelet therapy in patients with nonvalvular AF without a history of stroke and transient ischaemic attack [29] . The higher risk of gastrointestinal bleeding might be explained by the pharmacokinetic in the case of dabigatran. Dabigatran exilate is a prodrug that is hydrolysed to the active drug by esterase. This leads to progressively high concentrations of the active drug during transit in the gastrointestinal tract. This local effect might aggravate bleeding in (pre-)existing diseased mucosa [28] . However, this explanation is not applicable for rivaroxaban, which accounts for most prescriptions in the NOAC group for this study.
The study by Graham et al. [16] identified a trend for a higher risk of gastrointestinal bleeding with dabigatran compared with warfarin in women aged 75-84 years and ≥85 years. This is confirmed in our study where we also found an increased risk in major bleed for women, but not in men. These results are not in line with the differences found for sex in RCTs [10, 30] . It has been shown that dabigatran concentrations were dependent on several demographic characteristics including, among others, female sex [31] . In women, concentrations of dabigatran were 30% higher compared with men and higher plasma concentrations were found to be related with a higher probability of major bleed.
Further study should give more insight about the difference in benefit risk balance of antithrombotic agents for men and women.
In addition to those already identified, this study has several limitations. Benefit risk balance might be different for dabigatran and rivaroxaban and also across different dosages. This study lacked power to compare different NOACs or different dosages. Although we have adjusted the results for various risk factors, there might still be (unobserved) confounding. Despite the fact that the UK guidelines do not give a preference for either starting a NOAC or a VKA, we expect that these agents are prescribed to a selected group of people, which complicates comparison. Some misclassification of exposure might occur. If a patient starts a NOAC at day 1 of a specific month, it will take 29 days until this patient is classified as exposed in the next period. If they suffer a bleed on day 15, this will be wrongly attributed to nonexposure.
Despite the limitations, this study has several strengths, including inclusion of a diverse real-world population. We included all antithrombotic therapies used for AF in our investigation to provide a complete overview of efficacy and safety of these therapies. We have classified exposure in a time-dependent manner as well as confounders to minimize misclassification.
This study adds to the information that is already available on real life use of the different antithrombotic agents. The usage of NOACs poses a greater risk on major bleeding, especially on gastrointestinal bleeding, compared with the usage of VKAs. The use of NOACs in patients who are Table 4 Risk of major bleeding and ischaemic stroke in current NOAC and aspirin users compared with current VKA users stratified by sex 
